nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2D6—Fingolimod—multiple sclerosis	0.127	0.203	CbGbCtD
Bicalutamide—CYP3A4—Fingolimod—multiple sclerosis	0.0805	0.129	CbGbCtD
Bicalutamide—CYP2C19—Prednisone—multiple sclerosis	0.065	0.104	CbGbCtD
Bicalutamide—CYP3A4—Methylprednisolone—multiple sclerosis	0.0519	0.0831	CbGbCtD
Bicalutamide—CYP2C19—Dexamethasone—multiple sclerosis	0.0406	0.065	CbGbCtD
Bicalutamide—CYP3A4—Triamcinolone—multiple sclerosis	0.0393	0.063	CbGbCtD
Bicalutamide—CYP3A4—Mitoxantrone—multiple sclerosis	0.0379	0.0606	CbGbCtD
Bicalutamide—CYP2C9—Dexamethasone—multiple sclerosis	0.0338	0.054	CbGbCtD
Bicalutamide—CYP3A4—Betamethasone—multiple sclerosis	0.0337	0.054	CbGbCtD
Bicalutamide—CYP3A4—Prednisolone—multiple sclerosis	0.0333	0.0533	CbGbCtD
Bicalutamide—CYP3A4—Prednisone—multiple sclerosis	0.0314	0.0503	CbGbCtD
Bicalutamide—CYP2D6—Dexamethasone—multiple sclerosis	0.0309	0.0494	CbGbCtD
Bicalutamide—CYP3A4—Dexamethasone—multiple sclerosis	0.0196	0.0314	CbGbCtD
Bicalutamide—Enzalutamide—ALB—multiple sclerosis	0.0024	1	CrCbGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—HNRNPA1—multiple sclerosis	0.000365	0.0396	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.000328	0.0356	CbGpPWpGaD
Bicalutamide—Body temperature increased—Mitoxantrone—multiple sclerosis	0.0003	0.000825	CcSEcCtD
Bicalutamide—Myalgia—Triamcinolone—multiple sclerosis	0.000299	0.000821	CcSEcCtD
Bicalutamide—Vomiting—Azathioprine—multiple sclerosis	0.000299	0.000821	CcSEcCtD
Bicalutamide—Pneumonia—Methotrexate—multiple sclerosis	0.000298	0.00082	CcSEcCtD
Bicalutamide—Myalgia—Methylprednisolone—multiple sclerosis	0.000298	0.000819	CcSEcCtD
Bicalutamide—Anxiety—Methylprednisolone—multiple sclerosis	0.000297	0.000816	CcSEcCtD
Bicalutamide—Rash—Azathioprine—multiple sclerosis	0.000296	0.000814	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000296	0.000814	CcSEcCtD
Bicalutamide—Dermatitis—Azathioprine—multiple sclerosis	0.000296	0.000813	CcSEcCtD
Bicalutamide—Depression—Methotrexate—multiple sclerosis	0.000296	0.000813	CcSEcCtD
Bicalutamide—Headache—Azathioprine—multiple sclerosis	0.000294	0.000809	CcSEcCtD
Bicalutamide—Dry mouth—Triamcinolone—multiple sclerosis	0.000292	0.000803	CcSEcCtD
Bicalutamide—Angioedema—Dexamethasone—multiple sclerosis	0.000291	0.0008	CcSEcCtD
Bicalutamide—Angioedema—Betamethasone—multiple sclerosis	0.000291	0.0008	CcSEcCtD
Bicalutamide—Angiopathy—Prednisone—multiple sclerosis	0.000289	0.000794	CcSEcCtD
Bicalutamide—AR—Coregulation of Androgen receptor activity—ZMIZ1—multiple sclerosis	0.000289	0.0313	CbGpPWpGaD
Bicalutamide—Conjunctivitis—Methotrexate—multiple sclerosis	0.000288	0.000792	CcSEcCtD
Bicalutamide—Confusional state—Methylprednisolone—multiple sclerosis	0.000288	0.000792	CcSEcCtD
Bicalutamide—Immune system disorder—Prednisone—multiple sclerosis	0.000288	0.000791	CcSEcCtD
Bicalutamide—Oedema—Triamcinolone—multiple sclerosis	0.000286	0.000787	CcSEcCtD
Bicalutamide—Syncope—Dexamethasone—multiple sclerosis	0.000286	0.000785	CcSEcCtD
Bicalutamide—Syncope—Betamethasone—multiple sclerosis	0.000286	0.000785	CcSEcCtD
Bicalutamide—Arrhythmia—Prednisone—multiple sclerosis	0.000285	0.000782	CcSEcCtD
Bicalutamide—Infection—Triamcinolone—multiple sclerosis	0.000285	0.000782	CcSEcCtD
Bicalutamide—Sweating—Methotrexate—multiple sclerosis	0.000284	0.000781	CcSEcCtD
Bicalutamide—Infection—Methylprednisolone—multiple sclerosis	0.000284	0.00078	CcSEcCtD
Bicalutamide—Haematuria—Methotrexate—multiple sclerosis	0.000283	0.000777	CcSEcCtD
Bicalutamide—Shock—Triamcinolone—multiple sclerosis	0.000282	0.000774	CcSEcCtD
Bicalutamide—Insomnia—Prednisolone—multiple sclerosis	0.000282	0.000774	CcSEcCtD
Bicalutamide—Alopecia—Prednisone—multiple sclerosis	0.000281	0.000774	CcSEcCtD
Bicalutamide—Shock—Methylprednisolone—multiple sclerosis	0.000281	0.000773	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00028	0.000771	CcSEcCtD
Bicalutamide—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00028	0.00077	CcSEcCtD
Bicalutamide—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00028	0.000769	CcSEcCtD
Bicalutamide—Loss of consciousness—Betamethasone—multiple sclerosis	0.00028	0.000769	CcSEcCtD
Bicalutamide—Epistaxis—Methotrexate—multiple sclerosis	0.00028	0.000769	CcSEcCtD
Bicalutamide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00028	0.000769	CcSEcCtD
Bicalutamide—Paraesthesia—Prednisolone—multiple sclerosis	0.00028	0.000769	CcSEcCtD
Bicalutamide—Mental disorder—Prednisone—multiple sclerosis	0.000279	0.000767	CcSEcCtD
Bicalutamide—Nausea—Azathioprine—multiple sclerosis	0.000279	0.000767	CcSEcCtD
Bicalutamide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000278	0.000763	CcSEcCtD
Bicalutamide—Malnutrition—Prednisone—multiple sclerosis	0.000277	0.000762	CcSEcCtD
Bicalutamide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000277	0.000761	CcSEcCtD
Bicalutamide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000276	0.000759	CcSEcCtD
Bicalutamide—Hypertension—Betamethasone—multiple sclerosis	0.000275	0.000756	CcSEcCtD
Bicalutamide—Hypertension—Dexamethasone—multiple sclerosis	0.000275	0.000756	CcSEcCtD
Bicalutamide—Asthenia—Mitoxantrone—multiple sclerosis	0.000272	0.000749	CcSEcCtD
Bicalutamide—Myalgia—Dexamethasone—multiple sclerosis	0.000271	0.000745	CcSEcCtD
Bicalutamide—Myalgia—Betamethasone—multiple sclerosis	0.000271	0.000745	CcSEcCtD
Bicalutamide—Anxiety—Betamethasone—multiple sclerosis	0.00027	0.000742	CcSEcCtD
Bicalutamide—Anxiety—Dexamethasone—multiple sclerosis	0.00027	0.000742	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—multiple sclerosis	0.000268	0.000735	CcSEcCtD
Bicalutamide—Pain—Prednisolone—multiple sclerosis	0.000266	0.000732	CcSEcCtD
Bicalutamide—Haemorrhage—Methotrexate—multiple sclerosis	0.000266	0.000732	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—multiple sclerosis	0.000264	0.000726	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000263	0.000723	CcSEcCtD
Bicalutamide—Urethral disorder—Methotrexate—multiple sclerosis	0.000261	0.000717	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000261	0.000717	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00026	0.000716	CcSEcCtD
Bicalutamide—Oedema—Betamethasone—multiple sclerosis	0.00026	0.000714	CcSEcCtD
Bicalutamide—Oedema—Dexamethasone—multiple sclerosis	0.00026	0.000714	CcSEcCtD
Bicalutamide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00026	0.000714	CcSEcCtD
Bicalutamide—Insomnia—Triamcinolone—multiple sclerosis	0.000259	0.000712	CcSEcCtD
Bicalutamide—Insomnia—Methylprednisolone—multiple sclerosis	0.000258	0.00071	CcSEcCtD
Bicalutamide—Infection—Dexamethasone—multiple sclerosis	0.000258	0.00071	CcSEcCtD
Bicalutamide—Infection—Betamethasone—multiple sclerosis	0.000258	0.00071	CcSEcCtD
Bicalutamide—Paraesthesia—Triamcinolone—multiple sclerosis	0.000257	0.000707	CcSEcCtD
Bicalutamide—Feeling abnormal—Prednisolone—multiple sclerosis	0.000257	0.000705	CcSEcCtD
Bicalutamide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000257	0.000705	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—multiple sclerosis	0.000257	0.000705	CcSEcCtD
Bicalutamide—Anaemia—Prednisone—multiple sclerosis	0.000256	0.000704	CcSEcCtD
Bicalutamide—Shock—Dexamethasone—multiple sclerosis	0.000256	0.000703	CcSEcCtD
Bicalutamide—Shock—Betamethasone—multiple sclerosis	0.000256	0.000703	CcSEcCtD
Bicalutamide—Dyspnoea—Triamcinolone—multiple sclerosis	0.000255	0.000702	CcSEcCtD
Bicalutamide—Nervous system disorder—Betamethasone—multiple sclerosis	0.000255	0.0007	CcSEcCtD
Bicalutamide—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000255	0.0007	CcSEcCtD
Bicalutamide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000254	0.000699	CcSEcCtD
Bicalutamide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000254	0.000699	CcSEcCtD
Bicalutamide—Angioedema—Prednisone—multiple sclerosis	0.000253	0.000696	CcSEcCtD
Bicalutamide—Dyspepsia—Triamcinolone—multiple sclerosis	0.000252	0.000693	CcSEcCtD
Bicalutamide—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000252	0.000691	CcSEcCtD
Bicalutamide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000251	0.00069	CcSEcCtD
Bicalutamide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000251	0.00069	CcSEcCtD
Bicalutamide—Syncope—Prednisone—multiple sclerosis	0.000249	0.000683	CcSEcCtD
Bicalutamide—Anorexia—Betamethasone—multiple sclerosis	0.000248	0.000681	CcSEcCtD
Bicalutamide—Anorexia—Dexamethasone—multiple sclerosis	0.000248	0.000681	CcSEcCtD
Bicalutamide—Urticaria—Prednisolone—multiple sclerosis	0.000247	0.00068	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—multiple sclerosis	0.000247	0.000679	CcSEcCtD
Bicalutamide—Fatigue—Triamcinolone—multiple sclerosis	0.000247	0.000679	CcSEcCtD
Bicalutamide—Fatigue—Methylprednisolone—multiple sclerosis	0.000246	0.000677	CcSEcCtD
Bicalutamide—Pain—Triamcinolone—multiple sclerosis	0.000245	0.000673	CcSEcCtD
Bicalutamide—Loss of consciousness—Prednisone—multiple sclerosis	0.000244	0.00067	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—multiple sclerosis	0.000242	0.000664	CcSEcCtD
Bicalutamide—Vomiting—Mitoxantrone—multiple sclerosis	0.000241	0.000663	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—multiple sclerosis	0.00024	0.000661	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00024	0.000659	CcSEcCtD
Bicalutamide—Hypertension—Prednisone—multiple sclerosis	0.000239	0.000658	CcSEcCtD
Bicalutamide—Rash—Mitoxantrone—multiple sclerosis	0.000239	0.000658	CcSEcCtD
Bicalutamide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000239	0.000657	CcSEcCtD
Bicalutamide—Chills—Methotrexate—multiple sclerosis	0.000239	0.000657	CcSEcCtD
Bicalutamide—Headache—Mitoxantrone—multiple sclerosis	0.000238	0.000654	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000237	0.000651	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000237	0.000651	CcSEcCtD
Bicalutamide—Myalgia—Prednisone—multiple sclerosis	0.000236	0.000649	CcSEcCtD
Bicalutamide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000236	0.000649	CcSEcCtD
Bicalutamide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000235	0.000647	CcSEcCtD
Bicalutamide—Anxiety—Prednisone—multiple sclerosis	0.000235	0.000647	CcSEcCtD
Bicalutamide—Alopecia—Methotrexate—multiple sclerosis	0.000235	0.000647	CcSEcCtD
Bicalutamide—Insomnia—Betamethasone—multiple sclerosis	0.000235	0.000646	CcSEcCtD
Bicalutamide—Insomnia—Dexamethasone—multiple sclerosis	0.000235	0.000646	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000234	0.000644	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000234	0.000642	CcSEcCtD
Bicalutamide—Paraesthesia—Dexamethasone—multiple sclerosis	0.000233	0.000641	CcSEcCtD
Bicalutamide—Paraesthesia—Betamethasone—multiple sclerosis	0.000233	0.000641	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—multiple sclerosis	0.000233	0.000641	CcSEcCtD
Bicalutamide—AR—Nuclear Receptors—PGR—multiple sclerosis	0.000232	0.0252	CbGpPWpGaD
Bicalutamide—Malnutrition—Methotrexate—multiple sclerosis	0.000232	0.000637	CcSEcCtD
Bicalutamide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000229	0.000631	CcSEcCtD
Bicalutamide—Dyspepsia—Betamethasone—multiple sclerosis	0.000229	0.000629	CcSEcCtD
Bicalutamide—Dyspepsia—Dexamethasone—multiple sclerosis	0.000229	0.000629	CcSEcCtD
Bicalutamide—Urticaria—Triamcinolone—multiple sclerosis	0.000228	0.000625	CcSEcCtD
Bicalutamide—Urticaria—Methylprednisolone—multiple sclerosis	0.000227	0.000624	CcSEcCtD
Bicalutamide—Body temperature increased—Triamcinolone—multiple sclerosis	0.000226	0.000622	CcSEcCtD
Bicalutamide—Oedema—Prednisone—multiple sclerosis	0.000226	0.000622	CcSEcCtD
Bicalutamide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000226	0.000621	CcSEcCtD
Bicalutamide—Decreased appetite—Betamethasone—multiple sclerosis	0.000226	0.000621	CcSEcCtD
Bicalutamide—Decreased appetite—Dexamethasone—multiple sclerosis	0.000226	0.000621	CcSEcCtD
Bicalutamide—Nausea—Mitoxantrone—multiple sclerosis	0.000225	0.00062	CcSEcCtD
Bicalutamide—Infection—Prednisone—multiple sclerosis	0.000225	0.000618	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000224	0.000617	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000224	0.000617	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—multiple sclerosis	0.000224	0.000616	CcSEcCtD
Bicalutamide—Fatigue—Betamethasone—multiple sclerosis	0.000224	0.000616	CcSEcCtD
Bicalutamide—Fatigue—Dexamethasone—multiple sclerosis	0.000224	0.000616	CcSEcCtD
Bicalutamide—Shock—Prednisone—multiple sclerosis	0.000223	0.000612	CcSEcCtD
Bicalutamide—Pain—Dexamethasone—multiple sclerosis	0.000222	0.000611	CcSEcCtD
Bicalutamide—Pain—Betamethasone—multiple sclerosis	0.000222	0.000611	CcSEcCtD
Bicalutamide—Nervous system disorder—Prednisone—multiple sclerosis	0.000222	0.00061	CcSEcCtD
Bicalutamide—Skin disorder—Prednisone—multiple sclerosis	0.00022	0.000604	CcSEcCtD
Bicalutamide—Hyperhidrosis—Prednisone—multiple sclerosis	0.000219	0.000601	CcSEcCtD
Bicalutamide—Anorexia—Prednisone—multiple sclerosis	0.000216	0.000593	CcSEcCtD
Bicalutamide—Anaemia—Methotrexate—multiple sclerosis	0.000214	0.000589	CcSEcCtD
Bicalutamide—Feeling abnormal—Betamethasone—multiple sclerosis	0.000214	0.000589	CcSEcCtD
Bicalutamide—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000214	0.000589	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—ZMIZ1—multiple sclerosis	0.000213	0.0231	CbGpPWpGaD
Bicalutamide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000212	0.000584	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000212	0.000584	CcSEcCtD
Bicalutamide—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000211	0.00058	CcSEcCtD
Bicalutamide—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000211	0.000579	CcSEcCtD
Bicalutamide—Urticaria—Betamethasone—multiple sclerosis	0.000206	0.000567	CcSEcCtD
Bicalutamide—Urticaria—Dexamethasone—multiple sclerosis	0.000206	0.000567	CcSEcCtD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000206	0.0224	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000206	0.0224	CbGpPWpGaD
Bicalutamide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000206	0.000567	CcSEcCtD
Bicalutamide—Dizziness—Prednisolone—multiple sclerosis	0.000206	0.000566	CcSEcCtD
Bicalutamide—Asthenia—Triamcinolone—multiple sclerosis	0.000205	0.000565	CcSEcCtD
Bicalutamide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000205	0.000565	CcSEcCtD
Bicalutamide—Abdominal pain—Betamethasone—multiple sclerosis	0.000205	0.000565	CcSEcCtD
Bicalutamide—Body temperature increased—Betamethasone—multiple sclerosis	0.000205	0.000565	CcSEcCtD
Bicalutamide—Body temperature increased—Dexamethasone—multiple sclerosis	0.000205	0.000565	CcSEcCtD
Bicalutamide—Asthenia—Methylprednisolone—multiple sclerosis	0.000205	0.000564	CcSEcCtD
Bicalutamide—Insomnia—Prednisone—multiple sclerosis	0.000205	0.000563	CcSEcCtD
Bicalutamide—Paraesthesia—Prednisone—multiple sclerosis	0.000203	0.000559	CcSEcCtD
Bicalutamide—Pruritus—Triamcinolone—multiple sclerosis	0.000203	0.000557	CcSEcCtD
Bicalutamide—Cough—Methotrexate—multiple sclerosis	0.000202	0.000556	CcSEcCtD
Bicalutamide—Pruritus—Methylprednisolone—multiple sclerosis	0.000202	0.000556	CcSEcCtD
Bicalutamide—Dyspepsia—Prednisone—multiple sclerosis	0.000199	0.000548	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—multiple sclerosis	0.000197	0.000542	CcSEcCtD
Bicalutamide—Chest pain—Methotrexate—multiple sclerosis	0.000197	0.000542	CcSEcCtD
Bicalutamide—Decreased appetite—Prednisone—multiple sclerosis	0.000197	0.000541	CcSEcCtD
Bicalutamide—Rash—Prednisolone—multiple sclerosis	0.000196	0.00054	CcSEcCtD
Bicalutamide—Dermatitis—Prednisolone—multiple sclerosis	0.000196	0.000539	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000196	0.000539	CcSEcCtD
Bicalutamide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000196	0.000537	CcSEcCtD
Bicalutamide—Fatigue—Prednisone—multiple sclerosis	0.000195	0.000536	CcSEcCtD
Bicalutamide—Headache—Prednisolone—multiple sclerosis	0.000195	0.000536	CcSEcCtD
Bicalutamide—Constipation—Prednisone—multiple sclerosis	0.000194	0.000532	CcSEcCtD
Bicalutamide—Confusional state—Methotrexate—multiple sclerosis	0.000191	0.000524	CcSEcCtD
Bicalutamide—Dizziness—Triamcinolone—multiple sclerosis	0.000189	0.000521	CcSEcCtD
Bicalutamide—Dizziness—Methylprednisolone—multiple sclerosis	0.000189	0.000519	CcSEcCtD
Bicalutamide—Infection—Methotrexate—multiple sclerosis	0.000188	0.000516	CcSEcCtD
Bicalutamide—Feeling abnormal—Prednisone—multiple sclerosis	0.000186	0.000513	CcSEcCtD
Bicalutamide—Asthenia—Betamethasone—multiple sclerosis	0.000186	0.000512	CcSEcCtD
Bicalutamide—Asthenia—Dexamethasone—multiple sclerosis	0.000186	0.000512	CcSEcCtD
Bicalutamide—Nervous system disorder—Methotrexate—multiple sclerosis	0.000185	0.00051	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000185	0.000509	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000185	0.000509	CcSEcCtD
Bicalutamide—Nausea—Prednisolone—multiple sclerosis	0.000185	0.000508	CcSEcCtD
Bicalutamide—Pruritus—Betamethasone—multiple sclerosis	0.000184	0.000505	CcSEcCtD
Bicalutamide—Pruritus—Dexamethasone—multiple sclerosis	0.000184	0.000505	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—multiple sclerosis	0.000184	0.000505	CcSEcCtD
Bicalutamide—AR—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.000183	0.0199	CbGpPWpGaD
Bicalutamide—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000183	0.000503	CcSEcCtD
Bicalutamide—Vomiting—Triamcinolone—multiple sclerosis	0.000182	0.0005	CcSEcCtD
Bicalutamide—Vomiting—Methylprednisolone—multiple sclerosis	0.000182	0.000499	CcSEcCtD
Bicalutamide—Rash—Triamcinolone—multiple sclerosis	0.000181	0.000496	CcSEcCtD
Bicalutamide—Dermatitis—Triamcinolone—multiple sclerosis	0.00018	0.000496	CcSEcCtD
Bicalutamide—Anorexia—Methotrexate—multiple sclerosis	0.00018	0.000496	CcSEcCtD
Bicalutamide—Rash—Methylprednisolone—multiple sclerosis	0.00018	0.000495	CcSEcCtD
Bicalutamide—Dermatitis—Methylprednisolone—multiple sclerosis	0.00018	0.000495	CcSEcCtD
Bicalutamide—Urticaria—Prednisone—multiple sclerosis	0.00018	0.000494	CcSEcCtD
Bicalutamide—Headache—Triamcinolone—multiple sclerosis	0.000179	0.000493	CcSEcCtD
Bicalutamide—Headache—Methylprednisolone—multiple sclerosis	0.000179	0.000492	CcSEcCtD
Bicalutamide—Body temperature increased—Prednisone—multiple sclerosis	0.000179	0.000492	CcSEcCtD
Bicalutamide—Abdominal pain—Prednisone—multiple sclerosis	0.000179	0.000492	CcSEcCtD
Bicalutamide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000178	0.000489	CcSEcCtD
Bicalutamide—Diarrhoea—Betamethasone—multiple sclerosis	0.000178	0.000489	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000172	0.000474	CcSEcCtD
Bicalutamide—Dizziness—Betamethasone—multiple sclerosis	0.000172	0.000472	CcSEcCtD
Bicalutamide—Dizziness—Dexamethasone—multiple sclerosis	0.000172	0.000472	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—multiple sclerosis	0.000171	0.00047	CcSEcCtD
Bicalutamide—Nausea—Triamcinolone—multiple sclerosis	0.00017	0.000468	CcSEcCtD
Bicalutamide—Paraesthesia—Methotrexate—multiple sclerosis	0.00017	0.000467	CcSEcCtD
Bicalutamide—Nausea—Methylprednisolone—multiple sclerosis	0.00017	0.000467	CcSEcCtD
Bicalutamide—Dyspnoea—Methotrexate—multiple sclerosis	0.000169	0.000463	CcSEcCtD
Bicalutamide—Somnolence—Methotrexate—multiple sclerosis	0.000168	0.000462	CcSEcCtD
Bicalutamide—Hypersensitivity—Prednisone—multiple sclerosis	0.000167	0.000458	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—multiple sclerosis	0.000166	0.000458	CcSEcCtD
Bicalutamide—Vomiting—Dexamethasone—multiple sclerosis	0.000165	0.000454	CcSEcCtD
Bicalutamide—Vomiting—Betamethasone—multiple sclerosis	0.000165	0.000454	CcSEcCtD
Bicalutamide—Decreased appetite—Methotrexate—multiple sclerosis	0.000164	0.000452	CcSEcCtD
Bicalutamide—Rash—Dexamethasone—multiple sclerosis	0.000164	0.00045	CcSEcCtD
Bicalutamide—Rash—Betamethasone—multiple sclerosis	0.000164	0.00045	CcSEcCtD
Bicalutamide—Dermatitis—Dexamethasone—multiple sclerosis	0.000164	0.00045	CcSEcCtD
Bicalutamide—Dermatitis—Betamethasone—multiple sclerosis	0.000164	0.00045	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000163	0.000449	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—multiple sclerosis	0.000163	0.000448	CcSEcCtD
Bicalutamide—Headache—Betamethasone—multiple sclerosis	0.000163	0.000447	CcSEcCtD
Bicalutamide—Headache—Dexamethasone—multiple sclerosis	0.000163	0.000447	CcSEcCtD
Bicalutamide—Asthenia—Prednisone—multiple sclerosis	0.000162	0.000446	CcSEcCtD
Bicalutamide—AR—Nuclear Receptors—VDR—multiple sclerosis	0.000162	0.0176	CbGpPWpGaD
Bicalutamide—Pain—Methotrexate—multiple sclerosis	0.000162	0.000445	CcSEcCtD
Bicalutamide—Pruritus—Prednisone—multiple sclerosis	0.00016	0.00044	CcSEcCtD
Bicalutamide—Feeling abnormal—Methotrexate—multiple sclerosis	0.000156	0.000428	CcSEcCtD
Bicalutamide—Diarrhoea—Prednisone—multiple sclerosis	0.000155	0.000426	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000155	0.000425	CcSEcCtD
Bicalutamide—Nausea—Betamethasone—multiple sclerosis	0.000154	0.000424	CcSEcCtD
Bicalutamide—Nausea—Dexamethasone—multiple sclerosis	0.000154	0.000424	CcSEcCtD
Bicalutamide—Urticaria—Methotrexate—multiple sclerosis	0.00015	0.000413	CcSEcCtD
Bicalutamide—Dizziness—Prednisone—multiple sclerosis	0.00015	0.000411	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—multiple sclerosis	0.00015	0.000411	CcSEcCtD
Bicalutamide—Body temperature increased—Methotrexate—multiple sclerosis	0.00015	0.000411	CcSEcCtD
Bicalutamide—Vomiting—Prednisone—multiple sclerosis	0.000144	0.000395	CcSEcCtD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000144	0.0156	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000144	0.0156	CbGpPWpGaD
Bicalutamide—Rash—Prednisone—multiple sclerosis	0.000143	0.000392	CcSEcCtD
Bicalutamide—Dermatitis—Prednisone—multiple sclerosis	0.000143	0.000392	CcSEcCtD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000142	0.0154	CbGpPWpGaD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000142	0.0154	CbGpPWpGaD
Bicalutamide—Headache—Prednisone—multiple sclerosis	0.000142	0.00039	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ZMIZ1—multiple sclerosis	0.00014	0.0152	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Methotrexate—multiple sclerosis	0.000139	0.000383	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000136	0.0148	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000136	0.0148	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000136	0.0148	CbGpPWpGaD
Bicalutamide—Asthenia—Methotrexate—multiple sclerosis	0.000136	0.000373	CcSEcCtD
Bicalutamide—Nausea—Prednisone—multiple sclerosis	0.000134	0.000369	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—multiple sclerosis	0.000134	0.000368	CcSEcCtD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000132	0.0143	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000132	0.0143	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000131	0.0142	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000131	0.0142	CbGpPWpGaD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00013	0.0141	CbGpPWpGaD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00013	0.0141	CbGpPWpGaD
Bicalutamide—Diarrhoea—Methotrexate—multiple sclerosis	0.000129	0.000356	CcSEcCtD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000129	0.014	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000129	0.014	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.000128	0.0139	CbGpPWpGaD
Bicalutamide—Dizziness—Methotrexate—multiple sclerosis	0.000125	0.000344	CcSEcCtD
Bicalutamide—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00012	0.0131	CbGpPWpGaD
Bicalutamide—Vomiting—Methotrexate—multiple sclerosis	0.00012	0.000331	CcSEcCtD
Bicalutamide—Rash—Methotrexate—multiple sclerosis	0.000119	0.000328	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—multiple sclerosis	0.000119	0.000327	CcSEcCtD
Bicalutamide—Headache—Methotrexate—multiple sclerosis	0.000118	0.000326	CcSEcCtD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000116	0.0126	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000116	0.0126	CbGpPWpGaD
Bicalutamide—Nausea—Methotrexate—multiple sclerosis	0.000112	0.000309	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—IFNB1—multiple sclerosis	0.000112	0.0121	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000107	0.0116	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000107	0.0116	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000106	0.0115	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000106	0.0115	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.000105	0.0114	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000103	0.0112	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000103	0.0112	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—multiple sclerosis	8.85e-05	0.0096	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	8.64e-05	0.00937	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	8.64e-05	0.00937	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—multiple sclerosis	8.61e-05	0.00934	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	8.53e-05	0.00924	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	8.53e-05	0.00924	CbGpPWpGaD
Bicalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	7.75e-05	0.0084	CbGpPWpGaD
Bicalutamide—AR—Notch-mediated HES/HEY network—CD4—multiple sclerosis	7.56e-05	0.0082	CbGpPWpGaD
Bicalutamide—AR—Nongenotropic Androgen signaling—MAPK1—multiple sclerosis	7.42e-05	0.00805	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	7e-05	0.00759	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	7e-05	0.00759	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	6.75e-05	0.00732	CbGpPWpGaD
Bicalutamide—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	6.73e-05	0.0073	CbGpPWpGaD
Bicalutamide—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	6.19e-05	0.00671	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	6.19e-05	0.00671	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	6.19e-05	0.00671	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	6.1e-05	0.00662	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	6.1e-05	0.00662	CbGpPWpGaD
Bicalutamide—AR—Notch-mediated HES/HEY network—STAT3—multiple sclerosis	5.85e-05	0.00635	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	5.69e-05	0.00617	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	5.69e-05	0.00617	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	5.66e-05	0.00613	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	5.64e-05	0.00612	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	5.64e-05	0.00612	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	5.61e-05	0.00608	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	5.61e-05	0.00608	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	5.56e-05	0.00603	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	5.56e-05	0.00603	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	5.34e-05	0.00579	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL10—multiple sclerosis	5.1e-05	0.00553	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ZNF746—multiple sclerosis	5.06e-05	0.00548	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PTBP1—multiple sclerosis	4.63e-05	0.00501	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.54e-05	0.00492	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	4.45e-05	0.00483	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—multiple sclerosis	4.3e-05	0.00466	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.89e-05	0.00421	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	3.72e-05	0.00403	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	3.72e-05	0.00403	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	3.67e-05	0.00398	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	3.67e-05	0.00398	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—multiple sclerosis	3.55e-05	0.00385	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	3.52e-05	0.00382	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—STAT3—multiple sclerosis	3.51e-05	0.00381	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—HNRNPA1—multiple sclerosis	3.51e-05	0.0038	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—U2AF2—multiple sclerosis	3.51e-05	0.0038	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.23e-05	0.0035	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PGR—multiple sclerosis	3.17e-05	0.00344	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.97e-05	0.00322	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.95e-05	0.00319	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ZFP36L1—multiple sclerosis	2.77e-05	0.003	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	2.67e-05	0.0029	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.62e-05	0.00284	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.41e-05	0.00261	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.39e-05	0.00259	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.38e-05	0.00258	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.38e-05	0.00258	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—VDR—multiple sclerosis	2.21e-05	0.0024	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.17e-05	0.00235	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.17e-05	0.00235	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PABPC1—multiple sclerosis	2.15e-05	0.00233	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	2.14e-05	0.00232	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	2.09e-05	0.00227	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.94e-05	0.00211	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—TNF—multiple sclerosis	1.94e-05	0.0021	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—RPL5—multiple sclerosis	1.94e-05	0.0021	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.77e-05	0.00192	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.77e-05	0.00192	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.73e-05	0.00188	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.65e-05	0.00179	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.58e-05	0.00171	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL6—multiple sclerosis	1.57e-05	0.0017	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PGR—multiple sclerosis	1.53e-05	0.00165	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SRM—multiple sclerosis	1.5e-05	0.00163	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	1.39e-05	0.00151	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SRM—multiple sclerosis	1.38e-05	0.0015	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SRM—multiple sclerosis	1.37e-05	0.00148	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—POMC—multiple sclerosis	1.28e-05	0.00139	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	1.27e-05	0.00138	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—VDR—multiple sclerosis	1.07e-05	0.00116	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	1.06e-05	0.00115	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	1.06e-05	0.00115	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.03e-05	0.00112	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	9.73e-06	0.00106	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	9.73e-06	0.00106	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GPC5—multiple sclerosis	9.68e-06	0.00105	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	9.65e-06	0.00105	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	9.65e-06	0.00105	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	9.43e-06	0.00102	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SRM—multiple sclerosis	9.03e-06	0.000979	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GPC5—multiple sclerosis	8.9e-06	0.000965	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GPC5—multiple sclerosis	8.82e-06	0.000957	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—MYC—multiple sclerosis	8.8e-06	0.000954	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—POMC—multiple sclerosis	8.37e-06	0.000907	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RRM1—multiple sclerosis	8.02e-06	0.000869	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RRM1—multiple sclerosis	7.38e-06	0.0008	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RRM1—multiple sclerosis	7.31e-06	0.000793	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	6.36e-06	0.00069	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	6.36e-06	0.00069	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.22e-06	0.000674	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GPC5—multiple sclerosis	5.82e-06	0.000631	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.67e-06	0.000615	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.34e-06	0.000579	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.87e-06	0.000528	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.87e-06	0.000528	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RRM1—multiple sclerosis	4.82e-06	0.000523	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—BCHE—multiple sclerosis	4.61e-06	0.000499	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.44e-06	0.000482	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MYC—multiple sclerosis	4.24e-06	0.000459	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—BCHE—multiple sclerosis	4.24e-06	0.000459	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—BCHE—multiple sclerosis	4.2e-06	0.000455	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—APOE—multiple sclerosis	2.77e-06	0.0003	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.77e-06	0.0003	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—APOE—multiple sclerosis	2.55e-06	0.000276	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—APOE—multiple sclerosis	2.53e-06	0.000274	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—POMC—multiple sclerosis	2.38e-06	0.000258	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—POMC—multiple sclerosis	2.19e-06	0.000237	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—POMC—multiple sclerosis	2.17e-06	0.000235	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ALB—multiple sclerosis	2.17e-06	0.000235	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ALB—multiple sclerosis	2e-06	0.000216	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ALB—multiple sclerosis	1.98e-06	0.000215	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—APOE—multiple sclerosis	1.67e-06	0.000181	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—POMC—multiple sclerosis	1.43e-06	0.000155	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ALB—multiple sclerosis	1.3e-06	0.000141	CbGpPWpGaD
